DaVita shares jump after Q1 earnings as investors focus on margins, IKC growth

DaVita Inc. (DVA) shares rose to $195.99 after its first-quarter earnings, up 24.8% from $157.04 before the report, as investors reacted positively to stronger operating execution, cost control and productivity gains. Management said outperformance was driven by treatment volume, revenue per treatment and lower costs. CEO Javier Rodriguez cited continued momentum in the company’s Integrated Kidney Care business, including year-over-year improvements in quality and cost metrics under the CMS Comprehensive Kidney Care Contracting program. Investor focus in coming quarters is expected to center on whether productivity and digital investments can sustain margin expansion, the timing and scale of patient transfers from competitor clinic closures, and the effect of Affordable Care Act enrollment mix on revenue per treatment. Updates on artificial intelligence deployment and value-based care adoption may also influence the stock’s outlook.